Cancer Research: CHF 1.1 Million for Novochizol SA

EPFL and Novochizol SA to collaborate on designing more efficient immunotherapies, with the support of Innosuisse, the Swiss Innovation Agency. The EPFL Laboratory of Biomaterials for Immunoengineering, headed by Prof. Li Tang, and the BioArk Monthey– hosted startup company Novochizol SA possessing a unique chitosan transformation technology, today announced that Innosuisse will co-fund their collaborative …

Cancer Research: CHF 1.1 Million for Novochizol SA Read More »

Lonza plan to create 180 jobs in Visp by 2026

The pharmaceutical and biotechnology group Lonza has confirmed the extension of a long-term collaboration with a major global biopharmaceutical partner. The agreement will quadruple current bioconjugation capacity at the Ibex facilities in Visp. The new suites are expected to be operational in 2026 and will generate approximately 180 jobs, according to Lonza.

Siegfried and Lonza in the world’s top 10 CDMOs!

Two Swiss jewels in the crown of pharmaceutical subcontracting rank 1st and 6th in the world ranking published by Genetic Engineering & Biotechnology News.  Proof of a booming sector in our canton.

A test to detect deadly fungal infections is being developed in Valais

GaDia SA, a Valais-based start-up specializing in the development of diagnostic tests, and HES-SO Valais-Wallis are to collaborate on the development of a new-generation rapid test for the detection of fungal infections such as Invasive Pulmonary Aspergillosis (IPA). This research project is supported by Innosuisse, the Swiss innovation promotion agency, to the tune of CHF 350,000.

Scroll to Top